CD5 positive

P1, N=42, Recruiting, Baylor College of Medicine | Trial completion date: Sep 2039 --> Sep 2040 | Trial primary completion date: Jan 2024 --> Jan 2025

Collision tumors of IVLBCL are extremely rare. A better understanding of IVLBCL would help pathologists avoid misdiagnoses.

We highlight the critical role of platinum-based chemotherapy agents as a primary treatment modality in advanced thymic carcinoma, underscoring the efficacy of platinum as a first-line option for recurrent disease, even in cases previously treated with platinum. Additionally, our findings indicate that CD5 positivity could be associated with improved PFS, suggesting its potential as a prognostic marker.

More patients and longer follow-up are needed for validation. NCT0308190.

Although lymph nodes were not swollen at necropsy, histopathological examination revealed neoplastic lymphocyte proliferation in lymph nodes, which were immune positive for CD5 and CD20, and negative for CD3. The heifer was diagnosed with EBL caused by BLV classified as Group C.

Patients received therapies: R-CHOP intravenously Rituximab (375mg/m2 on Day0), Cyclophosphamide (750mg/m2on Day1), Doxorubicin (50mg/m2 on Day1), Vincristine(1. 4mg/m2 on Day1), and oral Prednisone(50mg/day Day1-5) with Zanubrutinib (160mg bid Day1-21) regimen...CONCLUSIONSOur results showed that Zanubrutinib plus R-CHOP(ZR-CHOP) is a safe and effective scheme for DLBCL patients with extranodal involvement. It indicate that the addition of zanubrutinib to the standard first-line treatment can enable these patients to achieve remission in the early stage of treatment and without significantly increasing toxicity.

Induction chemotherapy was given as per COG AALL1231 protocol with dose modifications including 50% decrease in vincristine and cyclophosphamide...He was given 150 mg/m2 for 7 days directly followed by nelarabine...Patients with AT have increased risk of toxicity from chemotherapy agents which requires dose modifications in their chemotherapy regimen. Venetoclax augmentation may be a viable approach for patients with AT or DNA repair disorders.

Thirty-two (78%) patients were treated with R-CHOP/RCHOP-like regimen, 3 (7%) with intensified chemotherapy and 4 (10%) handled palliative...To date, a more heterogeneous histological subtypes emerged, with PFS and OS at 2 years lower than expected in DLBCL. Further comparison between CD5- and CD5+ DLBCL should be pursued.

Hence, given the comparable remission rate and remarkable safety, autologous CD7 CAR T-cell therapy would be prioritized for recommendation for r/r T-ALL/LBL patients with low tumor load and access to collect enough normal T cells from their own body for CAR T-cell manufacture. CD5 CAR T-cell therapy is regarded as an option for patients with CD5 positive encountering treatment failure or relapse after CD7 CAR T-cell therapy.

Globally, autonomous BCR signalling strength across the CD5+ B-cell compartment appears to be correlated to the degree of clonal expansion. Fully malignant CLL cells overexpress genes of the oxidative phosphorylation pathway, presumably to meet increased energy demand from alternative sources.

Among the 348 patients, 62 (18%) received DA-EPOCH-R/HD-MTX, and 286 (82%) were treated with other R-chemo, such as R-CHOP (n = 254)... Our results confirmed favorable survival in the phase II study of DA-EPOCH-R/HD-MTX in clinical settings. DA-EPOCH-R/HD-MTX and IT MTX were associated with longer OS of patients with CD5+ DLBCL in our study cohort, warranting further investigation.

P2, N=35, Recruiting, National Cancer Center, Japan | Not yet recruiting --> Recruiting

With a preliminary diagnosis of primary cutaneous DLBCL, positron emission tomography (PET) scan was conducted that showed intense uptake in the groin lymph nodes and multifocal femur uptake concerning for osseous marrow involvement.  Accordingly, a diagnosis of systemic DLBCL was made.  The findings of CD5 positivity, dual expression of BCL-2 and C-Myc, and markedly elevated Ki-67 proliferative index are associated with a worse clinical outcome.  The cutaneous presentation and requirement of interdisciplinary collaboration highlight the importance of clinicopathologic correlation for accurate diagnosis. Poster type: Poster Defense

In conclusion, DNAJB1 and DDX3X, BTK, and a set of immunoglobulins are promising biomarkers. Probably, the suppression of BCR signaling is the unique phenotype of CD5-positive DLBCL. This formalin-fixed paraffin-embedded (FFPE)-based profiling may help to develop novel therapeutic molecularly targeted drugs for treating DLBCL.

The anti-tumor activity of CD5 CAR-T cells with a CD28 co-stimulation domain and C2C3 hinge region was superior to those with BB.z and 28.z domains. These preclinical data provided new insights into the factors dictating efficacy in T-ALL treatment with CAR-T cells and hold promise for clinical translation.

PD-1–positive TFH cell proliferation, although not specific, is a feature associated with peripheral T-cell lymphomas of TFH cell derivation, which increases diagnostic difficulties for MZL. Next-generation sequencing for lymphoma panel shows a pathogenic variant of TNFSRF14 C.215 G>A that has been reported in diffused large B-cell lymphoma but not in nodal MZL with plasmacytic differentiation.

Accelerated CLL with high Ki-67 index also must be ruled out. DLBCL cases are more likely non germinal center (100% in our study) and usually keep a similar immunophenotype as the previous CLL (CD5 and CD23 typically).

HCL is an indolent chronic lymphoproliferative disorder and diagnosis is usually straightforward. However, atypical expression of CD5 renders its differential diagnosis more difficult, but FC is a useful tool that allows an optimal classification of the disease and allows initiation of timely satisfactory therapy.

She followed up with Hematology/Oncology and was started on acalabrutinib twice daily... Regardless of the stage of the disease, CLL can be included in the differential diagnosis of possible causes of pleural effusion.

Patient was treated with intrathecal methotrexate, bendamustine, and rituximab prior to discharge home...Our patient had completed rituximab/cyclophosphamide/dexamethasone therapy four years prior to his presentation... It is important to identify extramedullary manifestations of WM as it has been shown in the literature to be associated with poor prognosis. It is unclear as to whether the number of extramedullary sites involved is directly correlated with mortality. Overall, patients with a diagnosis of WM and a new pleural effusion should undergo thoracentesis with pleural fluid analysis to determine whether there is extramedullary involvement, because although rare, this can affect prognosis and treatment of the disease.

The patient was diagnosed with pulmonary sarcoidosis and started on a Prednisone taper with significant improvement in his cough and dyspnea...Biopsies later revealed non-caseating granulomas with chronic inflammatory cells composed of few CD20 and CD79 positive B-cells and more CD3 and CD5 positive T-cells. A diagnosis of gastric sarcoidosis was made.

No abstract available

CD305 is a crucial marker in detecting bone marrow involvement in cases of B-cell NHL by MFC, particularly CD5 and CD10 negative lymphomas where detection of minimal BM involvement would be challenging without the incorporation of CD305 in the lymphoma screening panel. It also provides an aberrant expression as an additional abnormality in a significant proportion of samples and provides supporting evidence in the detection of minute tumor populations. Bone marrow involvement, Cytometry, Immunophenotype, B cell lymphoma

All cases were microsatellite stable, and the tumour mutational burden of the 5 cases was all < 1 mutations/Mb. WES showed higher mutation rates for N4BP1 (2/5), and many genetic alterations were related to the NF-kB signalling pathway, which is crucial for insight into the molecular mechanisms of the occurrence and development of ITC.

R-CHOP/R-CHOP-like was the most used treatment in first-line (22 patients), combined with radiotherapy in 6 patients (all with localized disease), and 3 (12%) patients received palliative regimens due to frailty... CD5+ DLBCL patients have diverse histologies, some of them related to poor prognosis, as leg-type, intravascular or EBV-positive DLBCL, which make difficult to believe that they constitute a homogeneous biological group, with BCL2 expressed in most of the cases. Of note, all the patients had extranodal involvement and many of them presented other features of poor prognosis at diagnosis, as high LDH and bulky disease. We will perform further comparisons between CD5+ and CD5- DLBCL cohorts to determine the real impact of this biomarker on survival.

P2, N=35, Not yet recruiting, National Cancer Center, Japan

Recently, the PEARL5 (a Phase II trial of DA-EPOCH and Rituximab with HD-MTX therapy for newly diagnosed DLBCL with CD5 expression) study demonstrated the efficacy of the DA-EPOCH-R (cyclophosphamide, etoposide, doxorubicin, vincristine, prednisone, and rituximab)/HD-MTX (high-dose methotrexate) regimen for CD5+ DLBCL...Complete remission rate and 1-year overall survival did not differ between the CD5-positive and -negative groups (90.0% vs 81.4%, p=0.853; 81.8% vs 76.9%, p=0.433). We conclude that the DA-EPOCH-R/HD-MTX regimen is effective for CD5+ DLBCL in this single institute analysis.

There are many similarities between CD5-positive SMZL and classical CD5-negative SMZL in clinical presentations, morphology and immunohistochemistry, but the former may have a more aggressive clinical course with a poorer prognosis.

However, every technology has challenges to overcome. In this review, CLL and its genetic abnormalities will be discussed, as well as the application of microarray technology as a diagnostic platform.

CD5 may regulate CCND2 through JAK-STAT signaling pathways, mediating tumor survival. This study provides independent adverse prognostic factors for risk assessment and treatment strategies for newly diagnosed DLBCL.

The current report highlights the importance of early diagnosis of CD5-positive DLBCL because of its poor prognosis and calls attention to the critical importance to identify immunodeficiencies because doing so affects the types of treatments available. Although cell-of-origin is useful for predicting outcomes, the germinal center B cell like and activated-B cell like subtypes remain heterogeneous, with better, and worse prognostic subsets within each group.

CD5- and CD10-positive DLBCL account for 0.5-1% of DLBCL cases and have a very poor disease prognosis. This is a rare case of CD5- and CD10-positive DLBCL with MYC and BCL2 expressions harboring MYD88 mutation.

P1, N=18, Recruiting, Beijing Boren Hospital | Trial primary completion date: Sep 2022 --> Sep 2023

Most cases of ALK+ ALCL highly express CD25 indicating that CD25 is a potential therapeutic target for ALCL patients. In this study, low CD25 expression identified a subset of ALK+ ALCL cases associated with older patient age, thrombocytopenia and shorter OS. These data suggest that assessing CD25 in ALK+ ALCL may be useful for guiding targeted therapy and in predicting prognosis of patients with ALK+ ALCL.

The diagnosis of ITC depends mainly on pathological and immunohistochemical results, particularly CD5 positive staining. Surgical resection is the preferred primary treatment modality which can be supplemented with radiotherapy and chemotherapy to reduce the risk of recurrence and metastasis.

Patients diagnosed with DLBCL at a high risk of CNS relapse between January 2003 and December 2020 were treated with frontline R-CHOP, R-CHOP-like, or dose-adjusted EPOCH-R chemotherapy...IT-MTX (15 mg/body) with hydrocortisone (25 mg/body) was administered four times, once weekly...The results were similar after adjusting for background factors with a propensity score-matched analysis. However, because CNS relapse is a rare event, a larger number of patients and longer follow-up periods are needed to confirm this conclusion.

P1, N=20, Recruiting, Xuanwu Hospital, Beijing

The addition of metformin significantly decreased the M2 proportion and the CD36 expression level in the coculture systems, indicating that metformin could target altered lipid metabolism and decrease M2 macrophages in DLBCL, especially in CD5+ non-DE lymphoma. In conclusion, enhanced lipid metabolism and M2 macrophage activation contributed to the immunosuppressive tumor microenvironment and could be potential therapeutic targets in CD5+ non-DE DLBCL.